RELEXXII Drug Patent Profile
✉ Email this page to a colleague
When do Relexxii patents expire, and what generic alternatives are available?
Relexxii is a drug marketed by Osmotica Pharm Us and is included in one NDA. There are five patents protecting this drug.
This drug has four patent family members in four countries.
The generic ingredient in RELEXXII is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Relexxii
A generic version of RELEXXII was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
US Patents and Regulatory Information for RELEXXII
RELEXXII is protected by five US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-007 | Jun 23, 2022 | RX | Yes | Yes | 10,265,308 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-006 | Jun 23, 2022 | RX | Yes | No | 9,855,258 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-007 | Jun 23, 2022 | RX | Yes | Yes | 9,855,258 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-006 | Jun 23, 2022 | RX | Yes | No | 9,827,234 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-001 | Jun 23, 2022 | RX | Yes | No | 10,695,336 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-004 | Jun 23, 2022 | RX | Yes | No | 9,855,258 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-005 | Jun 23, 2022 | RX | Yes | No | 9,827,234 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RELEXXII
See the table below for patents covering RELEXXII around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2992767 | FORME DE DOSAGE A LIBERATION CONTROLEE RESISTANT A LA LIBERATION MASSIVE (DOSE-DUMPING RESISTANT CONTROLLED RELEASE DOSAGE FORM) | ⤷ Start Trial |
| Argentina | 109157 | FORMA DE DOSIFICACIÓN DE LIBERACIÓN CONTROLADA RESISTENTE A LA LIBERACIÓN ABRUPTA DE LA DOSIS | ⤷ Start Trial |
| Canada | 2992767 | ⤷ Start Trial | |
| Uruguay | 37344 | ⤷ Start Trial | |
| Chile | 2017001919 | Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis. | ⤷ Start Trial |
| Chile | 2017001919 | ⤷ Start Trial | |
| Uruguay | 37344 | FORMA DE DOSIFICACIÓN DE LIBERACIÓN CONTROLADA RESISTENTE A LA LIBERACIÓN ABRUPTA DE LA DOSIS | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch